Dr. Reddy's Laboratories Limited (DRREDDY.BO)
| Previous close | 6,300.80 |
| Open | 6,324.00 |
| Bid | 6,266.95 x 0 |
| Ask | 6,251.45 x 0 |
| Day's range | 6,200.05 - 6,348.00 |
| 52-week range | 4,383.40 - 6,505.50 |
| Volume | |
| Avg. volume | 13,631 |
| Market cap | 1.042T |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 19.99 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 40.00 (0.63%) |
| Ex-dividend date | 11 Jul 2023 |
| 1y target est | N/A |
- Reuters
India's Dr Reddy's beats Q4 profit view; names new CFO
BENGALURU (Reuters) -India's generic drugmaker Dr Reddy's Laboratories reported fourth-quarter profit above expectations on Tuesday on higher U.S. and Europe sales, and appointed its new chief financial officer. M V Narasimham, who is currently the deputy CFO, will take over the role from Parag Agarwal, who held the post since 2020 and will retire on July 31. The company's U.S. sales have been boosted by persistently strong demand for Lenalidomide, a generic version of Bristol-Myers Squibb's blockbuster cancer drug Revlimid, which was launched in 2022.
- Zacks
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- Zacks
Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
